anthonyyazdaniml/CT-ADE-SOC huggingface dataset:
Intervention: Afatinib
Trial phase: Phase 3
ATC code: L01EB03 | L01XE13
SMILES: CN(C)C/C=C/C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 25
Group description: Afatinib (BIBW2992) is a film coated tablet. Patients were administered single daily dose of afatinib, starting at 40 milligram (mg) orally with water (~250 millilitre) up to a period of 80 weeks. The dose had to be escalated to 50 mg and/or reduced to 40 mg, 30 mg, or 20 mg.
Eligibility criteria:
Inclusion criteria:

Histologically or cytologically confirmed loco-regionally advanced head and neck squamous cell carcinoma (HNSCC), stage III to IVb
Unresected tumour prior to chemo-radiotherapy (CRT)
Concomitant CRT completed prior to randomisation
After concomitant platinum-based CRT, no evidence of disease (NED) on clinical and radiographic examinations
Eastern cooperative oncology group (ECOG) performance status 0 or 1

Exclusion criteria:

Patients with smoking history of less than or equal to 10 pack years and with primary tumour site of base of tongue and/or tonsil
Cancer of nasopharynx, sinuses, and/or salivary glands
Prior treatment with epidermal growth factor receptor (EGFR)-targeted small molecules, EGFR-targeted antibodies, and/or any investigational agents for HNSCC
Known pre-existing Interstitial Lung Disease (ILD)
Any past or present history of areca/betel-nut chewing or its derivatives for a cumulative duration of more than 3 months
Intervention: CLOBETASOL PROPIONATE
Trial phase: Phase 2
ATC code: D07AD01
SMILES: [H][C@@]12C[C@H](C)[C@](OC(=O)CC)(C(=O)CCl)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@@]21C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 24
Group description: applied twice a day for 15 days

DFD06 Cream
Eligibility criteria:
Inclusion Criteria:

Subjects must present with a clinical diagnosis of stable (at least 3 months) plaque psoriasis.

Subjects with psoriasis involving 20 to 50% Body Surface Area (BSA), not including the face, scalp, groin, axillae and other intertriginous areas.

Subjects must have an IGA grade of at least 3 (moderate) at the Baseline Visit Subjects whose results from the screening Adrenocorticotropic hormone (ACTH) stimulation test are considered normal (cortisol level >18 ug/dL at 30 minutes post stimulation) and show no other signs of abnormal HPA function or adrenal response

Exclusion Criteria:

Current diagnosis of unstable forms of psoriasis including guttate, erythrodermic, exfoliative or pustular psoriasis.

History of organ transplant requiring immunosuppression, HIV, or other immunocompromised state.

Have received treatment for any type of cancer within 5 years of the Baseline Visit except skin cancer and cervical cancer (in situ) are allowed if at least 1 year before the Baseline Visit.

Use within 60 days prior to the baseline Visit of: 1) immunosuppressive drugs (e.g., tacrolimus, pimecrolimus), or 2) systemic antipsoriatic treatment (e.g., methotrexate, cyclosporine, hydroxyurea) Use within 30 days prior to the Baseline Visit of: 1) topical antipsoriatic drugs (salicylic acid, anthralin, coal tar, calcipotriene), 2) psoralen and ultraviolet A (PUVA) therapy, 3) systemic anti-inflammatory agents (e.g., mycophenolate mofetil, sulfasalazine, 6-thioguanine), or 4) ultraviolet B (UVB) therapy.

Use within 30 days prior to the Screening Visit of any product containing corticosteroids. Inhaled, intraocular, intranasal, etc. steroids are not allowed.

Subjects who have an abnormal sleep schedule or work at night. Subjects with a known history of acute adrenal crisis, Addison's disease or decreased adrenal output, low pituitary function or pituitary tumors.

Subjects who have a history of an adverse reaction to cosyntropin injection or similar test reagents.

-
Intervention: Oxymetazoline Hydrochloride
Trial phase: Phase 3
SMILES: Cc1cc(C(C)(C)C)c(O)c(C)c1CC1=NCCN1.Cl
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 222
Group description: AGN-199201 applied to the face once daily for 29 days.
Eligibility criteria:
Inclusion Criteria:

-Moderate to severe persistent facial erythema associated with rosacea.

Exclusion Criteria:

Greater than 3 inflammatory lesions on the face
Current treatment with monoamine oxidase (MAO) inhibitors
Raynaud's syndrome, narrow angle glaucoma, orthostatic hypotension, scleroderma or Sjogren's syndrome.
Intervention: Vilaprisan
Trial phase: Phase 2
SMILES: C[C@]12C[C@H](c3ccc(S(C)(=O)=O)cc3)C3=C4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@@]2(O)C(F)(F)C(F)(F)F
Sex: Female
Age groups: Adult
Healthy volunteers: No
Participants at risk: 60
Group description: Subjects received 4 milligram (mg) VPR tablet once daily orally for 12 weeks (84 days) from the first week of the menstrual cycle following randomization.
Eligibility criteria:
Inclusion Criteria:

Signed and dated informed consent
Diagnosis of uterine fibroid(s) documented by transvaginal or abdominal ultrasound at screening with at least 1 fibroid with largest diameter 3.0 cm
18 to 50 years of age at the time of screening
Heavy menstrual bleeding >80 mL documented by MP during the bleeding episode following the screening visit
Normal or clinically insignificant cervical smear not requiring further follow-up
An endometrial biopsy performed at the screening visit 1 (Visit 1), without significant histological disorder such as endometrial hyperplasia or other significant endometrial pathology
Use of a non-hormonal barrier method of contraception starting at the bleeding episode following the screening visit 1 (Visit 1) until the end of the study
Good general health (except for findings related to uterine fibroids)

Exclusion Criteria:

Pregnancy or lactation
Uterine fibroid with largest diameter >10.0 cm
Hypersensitivity to any ingredient of the study drug
Laboratory values outside inclusion range before randomization and considered as clinically relevant
Hemoglobin values <6 g/dL or any condition requiring immediate blood transfusion (subjects with hemoglobin values <10.9 g/dL will receive iron supplementation)
Any diseases or conditions that can compromise the function of the body systems and could result in altered absorption, excessive accumulation, impaired metabolism, or altered excretion of the study drug
Intervention: Vilaprisan
Trial phase: Phase 2
SMILES: C[C@]12C[C@H](c3ccc(S(C)(=O)=O)cc3)C3=C4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@@]2(O)C(F)(F)C(F)(F)F
Sex: Female
Age groups: Adult
Healthy volunteers: No
Participants at risk: 61
Group description: Subjects received 2 mg VPR tablet once daily orally for 12 weeks (84 days) from the first week of the menstrual cycle following randomization.
Eligibility criteria:
Inclusion Criteria:

Signed and dated informed consent
Diagnosis of uterine fibroid(s) documented by transvaginal or abdominal ultrasound at screening with at least 1 fibroid with largest diameter 3.0 cm
18 to 50 years of age at the time of screening
Heavy menstrual bleeding >80 mL documented by MP during the bleeding episode following the screening visit
Normal or clinically insignificant cervical smear not requiring further follow-up
An endometrial biopsy performed at the screening visit 1 (Visit 1), without significant histological disorder such as endometrial hyperplasia or other significant endometrial pathology
Use of a non-hormonal barrier method of contraception starting at the bleeding episode following the screening visit 1 (Visit 1) until the end of the study
Good general health (except for findings related to uterine fibroids)

Exclusion Criteria:

Pregnancy or lactation
Uterine fibroid with largest diameter >10.0 cm
Hypersensitivity to any ingredient of the study drug
Laboratory values outside inclusion range before randomization and considered as clinically relevant
Hemoglobin values <6 g/dL or any condition requiring immediate blood transfusion (subjects with hemoglobin values <10.9 g/dL will receive iron supplementation)
Any diseases or conditions that can compromise the function of the body systems and could result in altered absorption, excessive accumulation, impaired metabolism, or altered excretion of the study drug
Intervention: Vilaprisan
Trial phase: Phase 2
SMILES: C[C@]12C[C@H](c3ccc(S(C)(=O)=O)cc3)C3=C4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@@]2(O)C(F)(F)C(F)(F)F
Sex: Female
Age groups: Adult
Healthy volunteers: No
Participants at risk: 61
Group description: Subjects received 1 mg VPR tablet once daily orally for 12 weeks (84 days) from the first week of the menstrual cycle following randomization.
Eligibility criteria:
Inclusion Criteria:

Signed and dated informed consent
Diagnosis of uterine fibroid(s) documented by transvaginal or abdominal ultrasound at screening with at least 1 fibroid with largest diameter 3.0 cm
18 to 50 years of age at the time of screening
Heavy menstrual bleeding >80 mL documented by MP during the bleeding episode following the screening visit
Normal or clinically insignificant cervical smear not requiring further follow-up
An endometrial biopsy performed at the screening visit 1 (Visit 1), without significant histological disorder such as endometrial hyperplasia or other significant endometrial pathology
Use of a non-hormonal barrier method of contraception starting at the bleeding episode following the screening visit 1 (Visit 1) until the end of the study
Good general health (except for findings related to uterine fibroids)

Exclusion Criteria:

Pregnancy or lactation
Uterine fibroid with largest diameter >10.0 cm
Hypersensitivity to any ingredient of the study drug
Laboratory values outside inclusion range before randomization and considered as clinically relevant
Hemoglobin values <6 g/dL or any condition requiring immediate blood transfusion (subjects with hemoglobin values <10.9 g/dL will receive iron supplementation)
Any diseases or conditions that can compromise the function of the body systems and could result in altered absorption, excessive accumulation, impaired metabolism, or altered excretion of the study drug
Intervention: Vilaprisan
Trial phase: Phase 2
SMILES: C[C@]12C[C@H](c3ccc(S(C)(=O)=O)cc3)C3=C4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@@]2(O)C(F)(F)C(F)(F)F
Sex: Female
Age groups: Adult
Healthy volunteers: No
Participants at risk: 60
Group description: Subjects received 0.5 mg VPR tablet once daily orally for 12 weeks (84 days) from the first week of the menstrual cycle following randomization.
Eligibility criteria:
Inclusion Criteria:

Signed and dated informed consent
Diagnosis of uterine fibroid(s) documented by transvaginal or abdominal ultrasound at screening with at least 1 fibroid with largest diameter 3.0 cm
18 to 50 years of age at the time of screening
Heavy menstrual bleeding >80 mL documented by MP during the bleeding episode following the screening visit
Normal or clinically insignificant cervical smear not requiring further follow-up
An endometrial biopsy performed at the screening visit 1 (Visit 1), without significant histological disorder such as endometrial hyperplasia or other significant endometrial pathology
Use of a non-hormonal barrier method of contraception starting at the bleeding episode following the screening visit 1 (Visit 1) until the end of the study
Good general health (except for findings related to uterine fibroids)

Exclusion Criteria:

Pregnancy or lactation
Uterine fibroid with largest diameter >10.0 cm
Hypersensitivity to any ingredient of the study drug
Laboratory values outside inclusion range before randomization and considered as clinically relevant
Hemoglobin values <6 g/dL or any condition requiring immediate blood transfusion (subjects with hemoglobin values <10.9 g/dL will receive iron supplementation)
Any diseases or conditions that can compromise the function of the body systems and could result in altered absorption, excessive accumulation, impaired metabolism, or altered excretion of the study drug
Intervention: Oxymetazoline Hydrochloride
Trial phase: Phase 3
SMILES: Cc1cc(C(C)(C)C)c(O)c(C)c1CC1=NCCN1.Cl
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 223
Group description: Oxymetazoline HCL Cream 1.0% applied to the face once daily for 29 days.
Eligibility criteria:
Inclusion Criteria:

-Moderate to severe persistent facial erythema associated with rosacea.

Exclusion Criteria:

Greater than 3 inflammatory lesions on the face
Current treatment with monoamine oxidase (MAO) inhibitors
Raynaud's syndrome, narrow angle glaucoma, orthostatic hypotension, scleroderma or Sjogren's syndrome.
Intervention: Cetirizine
Trial phase: Phase 3
ATC code: R06AE07 | R06AE09 | S01GX12
SMILES: O=C(O)COCCN1CCN(C(c2ccccc2)c2ccc(Cl)cc2)CC1
Sex: All
Age groups: Child | Adult | Older Adult
Healthy volunteers: No
Participants at risk: 171
Group description: 1 drop in each eye 2 times daily for up to 6 weeks AC-170 0%
Eligibility criteria:
Inclusion Criteria:

at least 2 years of age
be able to self-administer eye drops or have a parent/legal guardian available for this purpose
if less than 18 years old have a history or family history of atopic disease (including allergic conjunctivitis)
have ocular health within normal limits

Exclusion Criteria:

known contraindications or sensitivities to the study medication or its components
any ocular condition that, in the opinion of the investigator, could affect the subjects safety trial parameters
use of disallowed medication during the period indicated prior to the enrollment or during the study
Intervention: Nifedipine
Trial phase: Phase 3
ATC code: C07FB03 | C08CA05 | C08CA55 | C08GA01
SMILES: COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1c1ccccc1[N+](=O)[O-]
Sex: Female
Age groups: Child | Adult
Healthy volunteers: No
Participants at risk: 88
Group description: Women with preterm labor will receive nifedipine.

Nifedipine: Nifedipine 20 mg orally, then nifedipine 20 mg orally after 90 minutes if still contracting. Continue nifedipine 20 mg orally every 4 hours after the first dose for 48 hours.

Usual care: Usual evaluation, monitoring and care for women with preterm labor.
Eligibility criteria:
Inclusion Criteria:

Between 16 and 44 years of age inclusive
Singleton pregnancy
Intact membranes
Between 28-0/7 weeks and 33-6/7 weeks' gestation inclusive
Reported or documented uterine activity
Cervical dilation between 2 cm and 4 cm inclusive

Exclusion Criteria:

Multifetal gestation
Less than 28 weeks' gestation
34 or more weeks' gestation
Ruptured membranes
More than 4 cm dilated
Previously received a course of corticosteroids for fetal lung maturation
Oligohydramnios
Fetal growth restriction
Chorioamnionitis or temperature of at least 38.0 degrees Celsius
Fetal death
Preeclampsia
Suspected placental abruption or placenta previa
Lethal fetal malformation or amniotic fluid index at least 35
Systolic BP < 90 mmHg or diastolic BP < 50 mmHg
Baseline tachycardia (pulse >120 after 2 consecutive measurements 30 minutes apart)
Chronic hypertension treated with antihypertensives in pregnancy
Seizure disorder or HIV
Maternal allergy to nifedipine
Known maternal cardiac disease
Women who have received progesterone therapy in the second or third trimester for prevention of preterm birth
Intervention: Digoxin
Trial phase: Phase 3
ATC code: C01AA05
SMILES: [H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@@H](C5=CC(=O)OC5)CC[C@@]43O)[C@@]1(C)CC[C@H](O[C@H]1C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O[C@H]4C[C@H](O)[C@H](O)[C@@H](C)O4)[C@@H](C)O3)[C@@H](C)O1)C2
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 262
Group description: Patients randomized to this arm will be treated with an initial strategy of rate control. The target heart rate is < 100 beats per minute at rest. The treating clinician will choose agents from the list of rate control medications below and employ these medications (singly or in combination) to achieve rate control. A patient who presents with AF and slow ventricular response rate (<60 beats per minute) may still be randomized to the rate control strategy; in such instances, rate control agents may be withheld or administered in low doses. Dose ranges, as defined in guidelines, for each of the rate control agents need to be adhered to. Simultaneous use of more than one of the categories of rate control agents should be done with caution due to risk of bradycardia.

Rate Control Agents:

Beta blockers (e.g. metoprolol, atenolol, carvedilol, esmolol) Calcium channel blockers (nondihydropyridine) (e.g. diltiazem, verapamil) Digoxin
Eligibility criteria:
Enrollment Inclusion Criteria:

Age > 18 years
Undergoing heart surgery for coronary artery bypass (on-pump or off-pump CABG) and/or valve repair or replacement (excluding mechanical valves), including re-operations
Hemodynamically stable

Randomization Inclusion Criteria

AF that persists for > 60 minutes or recurrent (more than one) episodes of AF up to 7 days after surgery during the index hospitalization.

Exclusion Criteria:

LVAD insertion or heart transplantation
Maze procedure
TAVR
History of or planned mechanical valve replacement
Correction of complex congenital cardiac defect (excluding bicuspid aortic valve, atrial septal defect or PFO)
History of AF or AFL
History of AF or AFL ablation
Contraindications to warfarin or amiodarone
Need for long-term anticoagulation
Concurrent participation in an interventional (drug or device) trial
Intervention: Buspirone
Trial phase: Phase 2
ATC code: N05BE01
SMILES: O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(c2ncccn2)CC1
Sex: All
Age groups: Adult
Healthy volunteers: No
Participants at risk: 19
Group description: Buspirone is administered orally twice per day (9:00 AM and 6:00 PM) for 3 weeks. 10 mg buspirone is administered on days 1-4, then the dose is increased by 10 mg every 3 days to a maximum of 40 mg buspirone on days 10-19.
Eligibility criteria:
Inclusion Criteria:

Marijuana substance use disorder based on a score of ≥ 13 on the Cannabis Use Disorders Identification Test - Revised (CUDIT-R)
a score of ≥ 4 on the Cannabis Abuse Screening Test (CAST)
meeting criteria for a marijuana substance use disorder based on the Structured Clinical Interview for the Diagnostic and Statistical Manual of Mental Disorders IV (DSM-IV)

Exclusion Criteria:

Current DSM-IV Axis I disorder other than marijuana use disorder
serious medical illness requiring ongoing medical treatment, which could affect the central nervous system, or any other medical contraindication (e.g., renal, cardiovascular, pulmonary, blood) as determined by medical screening
a positive pregnancy test or breast feeding (females)
concomitant use of prescription medications that could affect the central nervous system
active suicidal ideation or Beck Depression Inventory II score greater than 19
positive urine drug screen for drugs other than marijuana or positive breath alcohol screen
Shipley-2 test of cognitive aptitude score outside 2 SD units of the published composite score average
smoking > 10 nicotine cigarettes per day / Fagerstrom Score > 4
taking meds known to have significant drug interactions with buspirone.
Intervention: Atorvastatin
Trial phase: Phase 4
ATC code: C10AA05 | C10BA05 | C10BX03 | C10BX06 | C10BX08 | C10BX11 | C10BX12 | C10BX15 | C10BX18 | C10BX19
SMILES: CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 1
Group description: Subjects will be treated with atorvastatin 10 mg/day for 30 days. The study team will obtain one blood and urine sample at baseline prior to starting atorvastatin therapy, and again after 30 days of drug therapy. The study team will do ultrasound imaging of the arm in which a probe will be placed over the blood vessels to measure the diameter of the artery and how this changes after a blood pressure cuff is inflated and then deflated. Subjects will take one nitroglycerine tablet during the ultrasound imaging.

Atorvastatin
Eligibility criteria:
Inclusion Criteria:

Stage 3, 4 and 5 chronic kidney disease (not on dialysis)
Hyperlipidemia requiring cholesterol lowering therapy
Aged 18 to 80 years old
Ability to provide informed consent

Exclusion Criteria:

Patients requiring multiple cholesterol reducing agents
Patients with neovascularization present, such as neoplasm, active wounds, or significant retinopathy
Patients with contraindications or allergy to statins
Intervention: Maraviroc
Trial phase: Not Applicable
ATC code: J05AX09
SMILES: Cc1nnc(C(C)C)n1[C@@H]1C[C@H]2CC[C@@H](C1)N2CC[C@H](NC(=O)C1CCC(F)(F)CC1)c1ccccc1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 3
Group description: All subjects with active stage II sarcoidosis with or without skin disease will receive the drug maraviroc 300mg to be taken orally twice a day for 6 weeks duration.

all subjects will receive maraviroc 300mg orally twice a day for 6 weeks

Bronchoscopy with bronchoalveolar lavage: Bronchoscopy employs a flexible instrument that is inserted into the trachea and proximal airways after topical anesthesia. Bronchoalveolar lavage involves the instillation of saline solution through the bronchoscope into the airways followed by recovery under suction to collects lung fluid containing cells and proteins.

venipunctures: Venipunctures will be performed at study entry, after two weeks, and at the end of the study to collect blood for research studies and safety laboratories.

Skin biopsy: For subjects with sarcoidosis skin lesions, an optional skin biopsy specimen may be collected for research studies.
Eligibility criteria:
Inclusion Criteria:

Histologically proven sarcoidosis from any site (noncaseating granulomas without other causes).
Diagnosis of active sarcoidosis (Sec. 5.5.4.t) clinical stage II by Chest X-ray (CXR).
Forced Vital Capacity (FVC) >45% and Diffusing Capacity for Carbon Monoxide (DLCO) >50% of predicted values.
Evidence of active sarcoidosis (see criteria above)
Able and willing to complete all study procedures (e.g., bronchoscopy, post-drug surveillance)
Age: 18+ years old (prevalence greatest in young adults; pediatric maraviroc safety not established).
Not on immunosuppression for sarcoidosis at the time of recruitment, (e.g., steroids, tumor necrosis factor alpha (TNF-a) blockade)
Liver function (transaminases, bilirubin), coagulation (International Normalized Ratio (INR), partial thromboplastin time (PTT), platelet count), blood urea nitrogen (BUN), creatinine, and white blood count (WBC) within normal limits.
If female: negative pregnancy test, agreement to use reliable contraception if of childbearing potential 30 days prior and for 30 days after study completion (drug safety during pregnancy not established).
Negative HIV and HBsAg tests

Exclusion Criteria:

Diagnosis of infection based upon clinical evaluation and/or microbial testing.
The diagnosis of any disease involving the heart, lungs, liver (HVC), kidney, hematologic, endocrine, or Gl systems which, in the judgment of the PI, would pose an undue risk to the subject if they participated in this study. This includes but is not limited to diabetes, uncontrolled hypertension, liver disease (HVC), or history of malignancy.
Medications that will either inhibit or induce CYP3A4 (including St John's Wort)
Intervention: Bivalirudin
Trial phase: Phase 4
ATC code: B01AE06
SMILES: CC[C@H](C)[C@H](NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(=O)O)NC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](N)Cc1ccccc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(=O)O
Sex: All
Age groups: Adult
Healthy volunteers: No
Participants at risk: 45
Group description: epidural anesthesia with 1% lidocaine 10ml before propofol TCI
Eligibility criteria:
Inclusion Criteria:

American Society of Anesthesiologists (ASA) I-II physical status,
aged 40-60 yr,
BMI 19-25 kg/m2,
undergoing elective gastrointestinal surgery

Exclusion Criteria:

patients with cardiovascular or neurological disease, drug or alcohol abuse and absolute contraindications for neuraxial blockade.